RxDoctor Payments Data

Mary Sahr

Acute Care · Circleville, OHNPI 1154692937

Payments from drug & device makers

$654in general payments, 2019–2025

Across 25 payments — averaging $26.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$196
  • Novartis$160
  • Abbott$144
  • Boehringer Ingelheim$77
  • Pfizer$41
  • Amgen$18
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$654100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer5$196
Novartis9$160
Abbott2$144
Boehringer Ingelheim5$77
Pfizer2$41
Amgen1$18
Novo Nordisk1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$654 in reported general payments places this provider in the 70th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$33,901
Medicare patients
231
Services billed
459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban276$197,381
JardianceEmpagliflozin196$163,068
EntrestoSacubitril/Valsartan136$109,019
XareltoRivaroxaban71$63,026
Repatha SureclickEvolocumab63$43,259
VascepaIcosapent Ethyl11$6,485
Ranolazine ErRanolazine27$4,995
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$3,008
Atorvastatin Calcium219$2,441
Metoprolol Succinate236$2,415
Flecainide Acetate72$2,267
Rosuvastatin Calcium131$1,565
Ezetimibe103$1,554
Amiodarone Hcl47$1,386
Metoprolol Tartrate171$1,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$197,381276 claims
Boehringer IngelheimJardiance$77$163,068196 claims
NovartisEntresto$160$109,019136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,101 acute care providers in Ohio.

Other acute care in Circleville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →